140 related articles for article (PubMed ID: 35817000)
1. Role of Sarcopenia in Advanced Malignant Cutaneous Melanoma Treated with Immunotherapy: A Meta-Analysis.
Surov A; Meyer HJ; Wienke A
Oncology; 2022; 100(9):498-504. PubMed ID: 35817000
[No Abstract] [Full Text] [Related]
2. Prognostic Impact of Sarcopenia on Clinical Outcomes in Malignancies Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Li S; Wang T; Tong G; Li X; You D; Cong M
Front Oncol; 2021; 11():726257. PubMed ID: 34513704
[TBL] [Abstract][Full Text] [Related]
3. Sarcopenia predicts overall survival in patients with malignant hematological diseases: A meta-analysis.
Surov A; Wienke A
Clin Nutr; 2021 Mar; 40(3):1155-1160. PubMed ID: 32768316
[TBL] [Abstract][Full Text] [Related]
4. Low skeletal muscle mass predicts relevant clinical outcomes in head and neck squamous cell carcinoma. A meta analysis.
Surov A; Wienke A
Ther Adv Med Oncol; 2021; 13():17588359211008844. PubMed ID: 34035838
[TBL] [Abstract][Full Text] [Related]
5. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
Franken MG; Leeneman B; Gheorghe M; Uyl-de Groot CA; Haanen JBAG; van Baal PHM
Eur J Cancer; 2019 Dec; 123():58-71. PubMed ID: 31670077
[TBL] [Abstract][Full Text] [Related]
6. Sarcopenia and prognosis of advanced cancer patients receiving immune checkpoint inhibitors: A comprehensive systematic review and meta-analysis.
Deng HY; Chen ZJ; Qiu XM; Zhu DX; Tang XJ; Zhou Q
Nutrition; 2021 Oct; 90():111345. PubMed ID: 34166897
[TBL] [Abstract][Full Text] [Related]
7. Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: a meta-analysis.
Takenaka Y; Oya R; Takemoto N; Inohara H
J Cachexia Sarcopenia Muscle; 2021 Oct; 12(5):1122-1135. PubMed ID: 34337889
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis.
Petrelli F; Ardito R; Merelli B; Lonati V; Cabiddu M; Seghezzi S; Barni S; Ghidini A
Melanoma Res; 2019 Feb; 29(1):1-12. PubMed ID: 30308577
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study.
Gullo G; Rubatto M; Fava P; Brizio M; Tonella L; Ribero S; Medri M; Avallone G; Mastorino L; Fierro MT; Stanganelli I; Quaglino P
Dermatol Ther; 2022 Jun; 35(6):e15492. PubMed ID: 35384181
[TBL] [Abstract][Full Text] [Related]
10. Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study.
Cortellini A; Bozzetti F; Palumbo P; Brocco D; Di Marino P; Tinari N; De Tursi M; Agostinelli V; Patruno L; Valdesi C; Mereu M; Verna L; Lanfiuti Baldi P; Venditti O; Cannita K; Masciocchi C; Barile A; McQuade JL; Ficorella C; Porzio G
Sci Rep; 2020 Jan; 10(1):1456. PubMed ID: 31996766
[TBL] [Abstract][Full Text] [Related]
11. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
Tomita Y; Moldovan M; Chang Lee R; Hsieh AH; Townsend A; Price T
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD012078. PubMed ID: 33210731
[TBL] [Abstract][Full Text] [Related]
12. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma.
Sasse AD; Sasse EC; Clark LG; Ulloa L; Clark OA
Cochrane Database Syst Rev; 2007 Jan; (1):CD005413. PubMed ID: 17253556
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of sarcopenia in patients with solid tumors: A meta-analysis based on 81,814 patients.
Surov A; Wienke A
JPEN J Parenter Enteral Nutr; 2022 Nov; 46(8):1761-1768. PubMed ID: 35633306
[TBL] [Abstract][Full Text] [Related]
14. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.
Mocellin S; Pasquali S; Rossi CR; Nitti D
J Natl Cancer Inst; 2010 Apr; 102(7):493-501. PubMed ID: 20179267
[TBL] [Abstract][Full Text] [Related]
15. Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients.
Basak EA; van der Meer JWM; Hurkmans DP; Schreurs MWJ; Oomen-de Hoop E; van der Veldt AAM; Bins S; Joosse A; Koolen SLW; Debets R; Peeters RP; Aerts JGJV; Mathijssen RHJ; Medici M
Thyroid; 2020 Jul; 30(7):966-973. PubMed ID: 32151195
[No Abstract] [Full Text] [Related]
16. Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis.
Sun Q; Sun H; Wu N; Hu Y; Zhang F; Cong X
Front Oncol; 2022; 12():976224. PubMed ID: 36185176
[TBL] [Abstract][Full Text] [Related]
17. Sarcopenia affects clinical efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients: A systematic review and meta-analysis.
Wang J; Cao L; Xu S
Int Immunopharmacol; 2020 Nov; 88():106907. PubMed ID: 33182031
[TBL] [Abstract][Full Text] [Related]
18. BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis.
Ny L; Hernberg M; Nyakas M; Koivunen J; Oddershede L; Yoon M; Wang X; Guyot P; Geisler J
Acta Oncol; 2020 Jul; 59(7):833-844. PubMed ID: 32285732
[No Abstract] [Full Text] [Related]
19. Metastatic melanoma: pretreatment contrast-enhanced CT texture parameters as predictive biomarkers of survival in patients treated with pembrolizumab.
Durot C; Mulé S; Soyer P; Marchal A; Grange F; Hoeffel C
Eur Radiol; 2019 Jun; 29(6):3183-3191. PubMed ID: 30645669
[TBL] [Abstract][Full Text] [Related]
20. Higher BMI, But Not Sarcopenia, Is Associated With Pembrolizumab-related Toxicity in Patients With Advanced Melanoma.
Hu JB; Ravichandran S; Rushing C; Beasley GM; Hanks BA; Jung SH; Salama AKS; Ho L; Mosca PJ
Anticancer Res; 2020 Sep; 40(9):5245-5254. PubMed ID: 32878813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
